Skip to main content
SpringerLink
Log in

Molecular Pathology of Lobular Carcinoma

  • Chapter
  • First Online:
Precision Molecular Pathology of Breast Cancer

Part of the book series: Molecular Pathology Library ((MPLB,volume 10))

  • 1577 Accesses

Abstract

Lobular breast carcinoma has distinct clinical, morphological and molecular features. Due to loss of E-cadherin molecule lobular breast carcinoma cells characteristically appear dyshesive. The loss of E-cadherin is due to an underlying molecular alteration in CDH1, the gene encoding E-cadherin protein. The majority of lobular breast carcinomas are of luminal A molecular subtype, which generally have a good prognosis. Molecular changes seen in other subtypes of lobular breast carcinomas appear similar to those seen in ductal breast carcinomas and may be associated with a worse prognosis.

This is a preview of subscription content, log in via an institution to check access.

Access this chapter

Log in via an institution
Chapter
USD 29.95
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
eBook
USD 99.00
Price excludes VAT (USA)
  • Available as EPUB and PDF
  • Read on any device
  • Instant download
  • Own it forever
Softcover Book
USD 129.00
Price excludes VAT (USA)
  • Compact, lightweight edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info
Hardcover Book
USD 119.99
Price excludes VAT (USA)
  • Durable hardcover edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info

Tax calculation will be finalised at checkout

Purchases are for personal use only

Institutional subscriptions

Similar content being viewed by others

References

  1. Foote FW, Stewart FW. Lobular carcinoma in situ: a rare form of mammary cancer. Am J Pathol. 1941;17(4):491–6.

    PubMed Central  CAS  PubMed  Google Scholar 

  2. Haagensen CD, et al. Lobular neoplasia (so-called lobular carcinoma in situ) of the breast. Cancer. 1978;42(2):737–69.

    CAS  PubMed  Google Scholar 

  3. Wheeler JE, et al. Lobular carcinoma in situ of the breast: long-term followup. Cancer. 1974;34(3):554–63.

    CAS  PubMed  Google Scholar 

  4. Andersen JA. Lobular carcinoma in situ: a long-term follow-up in 52 cases. Acta Pathol Microbiol Scand A. 1974;82(4):519–33.

    CAS  PubMed  Google Scholar 

  5. Brogi E, Murray MP, Corben AD. Lobular carcinoma, not only a classic. Breast J. 2010;16(Suppl 1):S10–4.

    PubMed  Google Scholar 

  6. Mastracci TL, et al. E-cadherin alterations in atypical lobular hyperplasia and lobular carcinoma in situ of the breast. Mod Pathol. 2005;18(6):741–51.

    CAS  PubMed  Google Scholar 

  7. De Leeuw WJ, et al. Simultaneous loss of E-cadherin and catenins in invasive lobular breast cancer and lobular carcinoma in situ. J Pathol. 1997;183(4):404–11.

    PubMed  Google Scholar 

  8. Vos CB, et al. E-cadherin inactivation in lobular carcinoma in situ of the breast: an early event in tumorigenesis. Br J Cancer. 1997;76(9):1131–3.

    PubMed Central  CAS  PubMed  Google Scholar 

  9. Arpino G, Laucirica R, Elledge RM. Premalignant and in situ breast disease: biology and clinical implications. Ann Intern Med. 2005;143(6):446–57.

    PubMed  Google Scholar 

  10. Rakha EA, Ellis IO. Lobular breast carcinoma and its variants. Semin Diagn Pathol. 2010;27(1):49–61.

    PubMed  Google Scholar 

  11. Simpson PT, et al. The diagnosis and management of pre-invasive breast disease: pathology of atypical lobular hyperplasia and lobular carcinoma in situ. Breast Cancer Res. 2003;5(5):258–62.

    PubMed Central  PubMed  Google Scholar 

  12. Lakhani SRE, Simpson PT. Invasive lobular carcinoma. In: Lakhani SEI, Schnitt SJ, Tan P-H, van de Vijver MJ, editors. WHO classification of tumors of the breast. Lyon: IARC; 2012.

    Google Scholar 

  13. Daling JR, et al. Relation of regimens of combined hormone replacement therapy to lobular, ductal, and other histologic types of breast carcinoma. Cancer. 2002;95(12):2455–64.

    CAS  PubMed  Google Scholar 

  14. Chen CL, et al. Hormone replacement therapy in relation to breast cancer. JAMA. 2002;287(6):734–41.

    CAS  PubMed  Google Scholar 

  15. Shetty MR. Infiltrating lobular carcinoma: is it different from infiltrating duct carcinoma? Cancer. 1994;74(3):986–7.

    CAS  PubMed  Google Scholar 

  16. Silverstein MJ, et al. Infiltrating lobular carcinoma: is it different from infiltrating duct carcinoma? Cancer. 1994;73(6):1673–7.

    CAS  PubMed  Google Scholar 

  17. Wheeler JE, Enterline HT. Lobular carcinoma of the breast in situ and infiltrating. Pathol Annu. 1976;11:161–88.

    CAS  PubMed  Google Scholar 

  18. Martinez V, Azzopardi JG. Invasive lobular carcinoma of the breast: incidence and variants. Histopathology. 1979;3(6):467–88.

    CAS  PubMed  Google Scholar 

  19. Fechner RE. Histologic variants of infiltrating lobular carcinoma of the breast. Hum Pathol. 1975;6(3):373–8.

    CAS  PubMed  Google Scholar 

  20. Shousha S, et al. Alveolar variant of invasive lobular carcinoma of the breast: a tumor rich in estrogen receptors. Am J Clin Pathol. 1986;85(1):1–5.

    CAS  PubMed  Google Scholar 

  21. Van Bogaert LJ, Maldague P. Infiltrating lobular carcinoma of the female breast: deviations from the usual histopathologic appearance. Cancer. 1980;45(5):979–84.

    PubMed  Google Scholar 

  22. Bentz JS, Yassa N, Clayton F. Pleomorphic lobular carcinoma of the breast: clinicopathologic features of 12 cases. Mod Pathol. 1998;11(9):814–22.

    CAS  PubMed  Google Scholar 

  23. Weidner N, Semple JP. Pleomorphic variant of invasive lobular carcinoma of the breast. Hum Pathol. 1992;23(10):1167–71.

    CAS  PubMed  Google Scholar 

  24. Eusebi V, Magalhaes F, Azzopardi JG. Pleomorphic lobular carcinoma of the breast: an aggressive tumor showing apocrine differentiation. Hum Pathol. 1992;23(6):655–62.

    CAS  PubMed  Google Scholar 

  25. Silver SA, Tavassoli FA. Pleomorphic carcinoma of the breast: clinicopathological analysis of 26 cases of an unusual high-grade phenotype of ductal carcinoma. Histopathology. 2000;36(6):505–14.

    CAS  PubMed  Google Scholar 

  26. Middleton LP, et al. Pleomorphic lobular carcinoma: morphology, immunohistochemistry, and molecular analysis. Am J Surg Pathol. 2000;24(12):1650–6.

    CAS  PubMed  Google Scholar 

  27. Gamallo C, et al. Correlation of E-cadherin expression with differentiation grade and histological type in breast carcinoma. Am J Pathol. 1993;142(4):987–93.

    PubMed Central  CAS  PubMed  Google Scholar 

  28. Simpson PT, et al. Molecular profiling pleomorphic lobular carcinomas of the breast: evidence for a common molecular genetic pathway with classic lobular carcinomas. J Pathol. 2008;215(3):231–44.

    CAS  PubMed  Google Scholar 

  29. Rasbridge SA, et al. Epithelial (E-) and placental (P-)cadherin cell adhesion molecule expression in breast carcinoma. J Pathol. 1993;169(2):245–50.

    CAS  PubMed  Google Scholar 

  30. Moll R, et al. Differential loss of E-cadherin expression in infiltrating ductal and lobular breast carcinomas. Am J Pathol. 1993;143(6):1731–42.

    PubMed Central  CAS  PubMed  Google Scholar 

  31. Takeichi M. Cadherin cell adhesion receptors as a morphogenetic regulator. Science. 1991;251(5000):1451–5.

    CAS  PubMed  Google Scholar 

  32. Golenhofen N, Drenckhahn D. The catenin, p120ctn, is a common membrane-associated protein in various epithelial and non-epithelial cells and tissues. Histochem Cell Biol. 2000;114(2):147–55.

    CAS  PubMed  Google Scholar 

  33. Hatzfeld M. The p120 family of cell adhesion molecules. Eur J Cell Biol. 2005;84(2–3):205–14.

    CAS  PubMed  Google Scholar 

  34. Davis MA, Ireton RC, Reynolds AB. A core function for p120-catenin in cadherin turnover. J Cell Biol. 2003;163(3):525–34.

    PubMed Central  CAS  PubMed  Google Scholar 

  35. Peifer M, Yap AS. Traffic control: p120-catenin acts as a gatekeeper to control the fate of classical cadherins in mammalian cells. J Cell Biol. 2003;163(3):437–40.

    PubMed Central  CAS  PubMed  Google Scholar 

  36. Sarrio D, et al. Cytoplasmic localization of p120ctn and E-cadherin loss characterize lobular breast carcinoma from preinvasive to metastatic lesions. Oncogene. 2004;23(19):3272–83.

    CAS  PubMed  Google Scholar 

  37. Shibata T, et al. Cytoplasmic p120ctn regulates the invasive phenotypes of E-cadherin-deficient breast cancer. Am J Pathol. 2004;164(6):2269–78.

    PubMed Central  CAS  PubMed  Google Scholar 

  38. Kanai Y, et al. Point mutation of the E-cadherin gene in invasive lobular carcinoma of the breast. Jpn J Cancer Res. 1994;85(10):1035–9.

    CAS  PubMed  Google Scholar 

  39. Droufakou S, et al. Multiple ways of silencing E-cadherin gene expression in lobular carcinoma of the breast. Int J Cancer. 2001;92(3):404–8.

    CAS  PubMed  Google Scholar 

  40. Berx G, et al. E-cadherin is a tumour/invasion suppressor gene mutated in human lobular breast cancers. EMBO J. 1995;14(24):6107–15.

    PubMed Central  CAS  PubMed  Google Scholar 

  41. Graff JR, et al. E-cadherin expression is silenced by DNA hypermethylation in human breast and prostate carcinomas. Cancer Res. 1995;55(22):5195–9.

    CAS  PubMed  Google Scholar 

  42. Yoshiura K, et al. Silencing of the E-cadherin invasion-suppressor gene by CpG methylation in human carcinomas. Proc Natl Acad Sci USA. 1995;92(16):7416–9.

    PubMed Central  CAS  PubMed  Google Scholar 

  43. Yonemura Y, et al. Decreased E-cadherin expression correlates with poor survival in patients with gastric cancer. Anal Cell Pathol. 1995;8(2):177–90.

    CAS  PubMed  Google Scholar 

  44. Berx G, et al. E-cadherin is inactivated in a majority of invasive human lobular breast cancers by truncation mutations throughout its extracellular domain. Oncogene. 1996;13(9):1919–25.

    CAS  PubMed  Google Scholar 

  45. Mohsin SK, et al. Biomarker profile and genetic abnormalities in lobular carcinoma in situ. Breast Cancer Res Treat. 2005;90(3):249–56.

    PubMed  Google Scholar 

  46. Cancer Genome Atlas Network. Comprehensive molecular portraits of human breast tumours. Nature. 2012;490(7418):61–70.

    Google Scholar 

  47. Da Silva L, et al. Aberrant expression of E-cadherin in lobular carcinomas of the breast. Am J Surg Pathol. 2008;32(5):773–83.

    PubMed  Google Scholar 

  48. Zhao L, et al. Diagnostic role of immunohistochemistry in the evaluation of breast pathology specimens. Arch Pathol Lab Med. 2014;138(1):16–24.

    PubMed  Google Scholar 

  49. Rakha EA, et al. Clinical and biological significance of E-cadherin protein expression in invasive lobular carcinoma of the breast. Am J Surg Pathol. 2010;34(10):1472–9.

    PubMed  Google Scholar 

  50. Lopez-Garcia MA, et al. Breast cancer precursors revisited: molecular features and progression pathways. Histopathology. 2010;57(2):171–92.

    PubMed  Google Scholar 

  51. Sorlie T, et al. Repeated observation of breast tumor subtypes in independent gene expression data sets. Proc Natl Acad Sci USA. 2003;100(14):8418–23.

    PubMed Central  CAS  PubMed  Google Scholar 

  52. Perou CM, et al. Molecular portraits of human breast tumours. Nature. 2000;406(6797):747–52.

    CAS  PubMed  Google Scholar 

  53. Sorlie T, et al. Gene expression patterns of breast carcinomas distinguish tumor subclasses with clinical implications. Proc Natl Acad Sci USA. 2001;98(19):10869–74.

    PubMed Central  CAS  PubMed  Google Scholar 

  54. Gatza ML, et al. A pathway-based classification of human breast cancer. Proc Natl Acad Sci USA. 2010;107(15):6994–9.

    PubMed Central  CAS  PubMed  Google Scholar 

  55. Stephens PJ, et al. Complex landscapes of somatic rearrangement in human breast cancer genomes. Nature. 2009;462(7276):1005–10.

    PubMed Central  CAS  PubMed  Google Scholar 

  56. Andre F, Pusztai L. Molecular classification of breast cancer: implications for selection of adjuvant chemotherapy. Nat Clin Pract Oncol. 2006;3(11):621–32.

    PubMed  Google Scholar 

  57. Reis-Filho JS, Westbury C, Pierga JY. The impact of expression profiling on prognostic and predictive testing in breast cancer. J Clin Pathol. 2006;59(3):225–31.

    PubMed Central  CAS  PubMed  Google Scholar 

  58. Geyer FC, et al. Genetic characterization of breast cancer and implications for clinical management. J Cell Mol Med. 2009;13(10):4090–103.

    PubMed Central  CAS  PubMed  Google Scholar 

  59. Geyer FC, Reis-Filho JS. Microarray-based gene expression profiling as a clinical tool for breast cancer management: are we there yet? Int J Surg Pathol. 2009;17(4):285–302.

    CAS  Google Scholar 

  60. Weigelt B, Baehner FL, Reis-Filho JS. The contribution of gene expression profiling to breast cancer classification, prognostication and prediction: a retrospective of the last decade. J Pathol. 2010;220(2):263–80.

    CAS  PubMed  Google Scholar 

  61. Rouzier R, et al. Breast cancer molecular subtypes respond differently to preoperative chemotherapy. Clin Cancer Res. 2005;11(16):5678–85.

    CAS  PubMed  Google Scholar 

  62. Livasy CA, et al. Phenotypic evaluation of the basal-like subtype of invasive breast carcinoma. Mod Pathol. 2006;19(2):264–71.

    CAS  PubMed  Google Scholar 

  63. Nielsen TO, et al. Immunohistochemical and clinical characterization of the basal-like subtype of invasive breast carcinoma. Clin Cancer Res. 2004;10(16):5367–74.

    CAS  PubMed  Google Scholar 

  64. Cheang MC, et al. Basal-like breast cancer defined by five biomarkers has superior prognostic value than triple-negative phenotype. Clin Cancer Res. 2008;14(5):1368–76.

    CAS  PubMed  Google Scholar 

  65. Bhargava R, Dabbs DJ. Use of immunohistochemistry in diagnosis of breast epithelial lesions. Adv Anat Pathol. 2007;14(2):93–107.

    PubMed  Google Scholar 

  66. Turner NC, Reis-Filho JS. Basal-like breast cancer and the BRCA1 phenotype. Oncogene. 2006;25(43):5846–53.

    CAS  PubMed  Google Scholar 

  67. Foulkes WD, et al. The prognostic implication of the basal-like (cyclin E high/p27 low/p53+/glomeruloid-microvascular-proliferation+) phenotype of BRCA1-related breast cancer. Cancer Res. 2004;64(3):830–5.

    CAS  PubMed  Google Scholar 

  68. Weigelt B, et al. Refinement of breast cancer classification by molecular characterization of histological special types. J Pathol. 2008;216(2):141–50.

    CAS  PubMed  Google Scholar 

  69. Soomro S, et al. c-erbB-2 expression in different histological types of invasive breast carcinoma. J Clin Pathol. 1991;44(3):211–4.

    PubMed Central  CAS  PubMed  Google Scholar 

  70. Rakha EA, et al. Invasive lobular carcinoma of the breast: response to hormonal therapy and outcomes. Eur J Cancer. 2008;44(1):73–83.

    PubMed  Google Scholar 

  71. Arpino G, et al. Infiltrating lobular carcinoma of the breast: tumor characteristics and clinical outcome. Breast Cancer Res. 2004;6(3):R149–56.

    PubMed Central  PubMed  Google Scholar 

  72. Radhi JM. Immunohistochemical analysis of pleomorphic lobular carcinoma: higher expression of p53 and chromogranin and lower expression of ER and PgR. Histopathology. 2000;36(2):156–60.

    CAS  PubMed  Google Scholar 

  73. Zhao H, et al. Different gene expression patterns in invasive lobular and ductal carcinomas of the breast. Mol Biol Cell. 2004;15(6):2523–36.

    PubMed Central  CAS  PubMed  Google Scholar 

  74. Weigelt B, et al. The molecular underpinning of lobular histological growth pattern: a genome-wide transcriptomic analysis of invasive lobular carcinomas and grade- and molecular subtype-matched invasive ductal carcinomas of no special type. J Pathol. 2010;220(1):45–57.

    CAS  PubMed  Google Scholar 

  75. Turashvili G, et al. Novel markers for differentiation of lobular and ductal invasive breast carcinomas by laser microdissection and microarray analysis. BMC Cancer. 2007;7:55.

    PubMed Central  PubMed  Google Scholar 

  76. Korkola JE, et al. Differentiation of lobular versus ductal breast carcinomas by expression microarray analysis. Cancer Res. 2003;63(21):7167–75.

    CAS  PubMed  Google Scholar 

  77. Nishizaki T, et al. Genetic alterations in lobular breast cancer by comparative genomic hybridization. Int J Cancer. 1997;74(5):513–7.

    CAS  PubMed  Google Scholar 

  78. Loo LW, et al. Array comparative genomic hybridization analysis of genomic alterations in breast cancer subtypes. Cancer Res. 2004;64(23):8541–9.

    CAS  PubMed  Google Scholar 

  79. Hwang ES, et al. Clonality of lobular carcinoma in situ and synchronous invasive lobular carcinoma. Cancer. 2004;100(12):2562–72.

    PubMed  Google Scholar 

  80. Masuda S. Breast cancer pathology: the impact of molecular taxonomy on morphological taxonomy. Pathol Int. 2012;62(5):295–302.

    CAS  PubMed  Google Scholar 

  81. Lu YJ, et al. Comparative genomic hybridization analysis of lobular carcinoma in situ and atypical lobular hyperplasia and potential roles for gains and losses of genetic material in breast neoplasia. Cancer Res. 1998;58(20):4721–7.

    CAS  PubMed  Google Scholar 

  82. Lakhani SR, et al. Loss of heterozygosity in lobular carcinoma in situ of the breast. Clin Mol Pathol. 1995;48(2):M74–8.

    PubMed Central  CAS  PubMed  Google Scholar 

  83. Nayar R, et al. Loss of heterozygosity on chromosome 11q13 in lobular lesions of the breast using tissue microdissection and polymerase chain reaction. Hum Pathol. 1997;28(3):277–82.

    CAS  PubMed  Google Scholar 

  84. Shin SJ, et al. Florid lobular carcinoma in situ: molecular profiling and comparison to classic lobular carcinoma in situ and pleomorphic lobular carcinoma in situ. Hum Pathol. 2013;44(10):1998–2009.

    CAS  PubMed  Google Scholar 

  85. Mastracci TL, et al. Genomic alterations in lobular neoplasia: a microarray comparative genomic hybridization signature for early neoplastic proliferation in the breast. Genes Chromosomes Cancer. 2006;45(11):1007–17.

    CAS  PubMed  Google Scholar 

  86. Chen YY, et al. Genetic and phenotypic characteristics of pleomorphic lobular carcinoma in situ of the breast. Am J Surg Pathol. 2009;33(11):1683–94.

    PubMed Central  PubMed  Google Scholar 

  87. Boldt V, et al. Positioning of necrotic lobular intraepithelial neoplasias (LIN, grade 3) within the sequence of breast carcinoma progression. Genes Chromosom Cancer. 2010;49(5):463–70.

    CAS  PubMed  Google Scholar 

  88. Reis-Filho JS, et al. Pleomorphic lobular carcinoma of the breast: role of comprehensive molecular pathology in characterization of an entity. J Pathol. 2005;207(1):1–13.

    CAS  PubMed  Google Scholar 

  89. Ross JS, et al. Relapsed classic E-cadherin (CDH1)-mutated invasive lobular breast cancer shows a high frequency of HER2 (ERBB2) gene mutations. Clin Cancer Res. 2013;19(10):2668–76.

    CAS  PubMed  Google Scholar 

  90. Green AR, et al. Loss of expression of chromosome 16q genes DPEP1 and CTCF in lobular carcinoma in situ of the breast. Breast Cancer Res Treat. 2009;113(1):59–66.

    CAS  PubMed  Google Scholar 

  91. Banerji S, et al. Sequence analysis of mutations and translocations across breast cancer subtypes. Nature. 2012;486(7403):405–9.

    PubMed Central  CAS  PubMed  Google Scholar 

  92. Sjoblom T, et al. The consensus coding sequences of human breast and colorectal cancers. Science. 2006;314(5797):268–74.

    PubMed  Google Scholar 

  93. Samuels Y, et al. High frequency of mutations of the PIK3CA gene in human cancers. Science. 2004;304(5670):554.

    CAS  PubMed  Google Scholar 

  94. Carpten JD, et al. A transforming mutation in the pleckstrin homology domain of AKT1 in cancer. Nature. 2007;448(7152):439–44.

    CAS  PubMed  Google Scholar 

  95. Usary J, et al. Mutation of GATA3 in human breast tumors. Oncogene. 2004;23(46):7669–78.

    CAS  PubMed  Google Scholar 

  96. Kan Z, et al. Diverse somatic mutation patterns and pathway alterations in human cancers. Nature. 2010;466(7308):869–73.

    CAS  PubMed  Google Scholar 

  97. Derksen PW, et al. Mammary-specific inactivation of E-cadherin and p53 impairs functional gland development and leads to pleomorphic invasive lobular carcinoma in mice. Dis Model Mech. 2011;4(3):347–58.

    PubMed Central  CAS  PubMed  Google Scholar 

  98. Dabbs DJ, et al. Lobular neoplasia of the breast revisited with emphasis on the role of E-cadherin immunohistochemistry. Am J Surg Pathol. 2013;37(7):e1–11.

    PubMed  Google Scholar 

  99. Shah SP, et al. Mutational evolution in a lobular breast tumour profiled at single nucleotide resolution. Nature. 2009;461(7265):809–13.

    CAS  PubMed  Google Scholar 

  100. Wilkerson PM, Reis-Filho JS. The 11q13–q14 amplicon: clinicopathological correlations and potential drivers. Genes Chromosom Cancer. 2013;52(4):333–55.

    CAS  PubMed  Google Scholar 

  101. Natrajan R, et al. An integrative genomic and transcriptomic analysis reveals molecular pathways and networks regulated by copy number aberrations in basal-like, HER2 and luminal cancers. Breast Cancer Res Treat. 2010;121(3):575–89.

    CAS  PubMed  Google Scholar 

  102. Weigelt B, Reis-Filho JS. Histological and molecular types of breast cancer: is there a unifying taxonomy? Nat Rev Clin Oncol. 2009;6(12):718–30.

    CAS  PubMed  Google Scholar 

  103. Stephens PJ, et al. The landscape of cancer genes and mutational processes in breast cancer. Nature. 2012;486(7403):400–4.

    PubMed Central  CAS  PubMed  Google Scholar 

  104. Gatza M. Genomic characterization of invasive lobular breast carcinoma. 2014. Available from: http://www.genome.gov/multimedia/slides/tcga3/21_gatza.pdf.

  105. Sawyer E, et al. Genetic predisposition to in situ and invasive lobular carcinoma of the breast. PLoS Genet. 2014;10(4):e1004285.

    PubMed Central  PubMed  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Department of Pathology, University of Massachusetts Medical School, UMassMemorial Medical Center, Three Biotech, One Innovation Drive, Worcester, MA, 01605, USA

    Ali Sakhdari, Lloyd Hutchinson & Ediz F. Cosar

Authors
  1. Ali Sakhdari
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Lloyd Hutchinson
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Ediz F. Cosar
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Ediz F. Cosar .

Editor information

Editors and Affiliations

  1. Department of Pathology, University of Massachusetts Medical School, UMassMemorial Medical Center, Worcester, Massachusetts, USA

    Ashraf Khan

  2. Department of Histopathology, University of Nottingham, Nottingham, United Kingdom

    Ian O. Ellis

  3. Leeds Institute of Cancer and Pathology, St. James University Hospital, Leeds, West Yorkshire, United Kingdom

    Andrew M. Hanby

  4. Department of Pathology, University of Massachusetts Medical School, UMassMemorial Medical Center, Worcester, Massachusetts, USA

    Ediz F. Cosar

  5. Department of Histopathology, University of Nottingham, Nottingham, United Kingdom

    Emad A. Rakha

  6. Department of Pathology, University of Massachusetts Medical School, UMassMemorial Medical Center, Worcester, Massachusetts, USA

    Dina Kandil

Rights and permissions

Reprints and permissions

Copyright information

© 2015 Springer Science+Business Media New York

About this chapter

Cite this chapter

Sakhdari, A., Hutchinson, L., Cosar, E.F. (2015). Molecular Pathology of Lobular Carcinoma. In: Khan, A., Ellis, I., Hanby, A., Cosar, E., Rakha, E., Kandil, D. (eds) Precision Molecular Pathology of Breast Cancer. Molecular Pathology Library, vol 10. Springer, New York, NY. https://doi.org/10.1007/978-1-4939-2886-6_7

Download citation

  • DOI: https://doi.org/10.1007/978-1-4939-2886-6_7

  • Published:

  • Publisher Name: Springer, New York, NY

  • Print ISBN: 978-1-4939-2885-9

  • Online ISBN: 978-1-4939-2886-6

  • eBook Packages: MedicineMedicine (R0)

Publish with us

Policies and ethics

Search

Navigation